News
| Curiosis X Medipost! | |
|---|---|
|
관리자
2026-06-22
Curiosis has entered into a Memorandum of Understanding (MOU) with Medipost, a leading stem cell therapeutics company, to optimize large-scale cell therapy manufacturing processes. A key technology in this collaboration is Celloger® Stack-H, the world’s first live-cell imaging system designed specifically for multi-layer cell culture vessels. The system is compatible with Corning HYPERStack® and Thermo Fisher Nunc™ Cell Factory™ platforms, enabling non-invasive monitoring of cells throughout the cultivation process. Celloger® Stack-H enables real-time cell monitoring and quantitative analysis in large-scale culture environments, providing greater visibility into cell growth and culture conditions throughout the manufacturing process. Key Application Areas • Cell & Gene Therapy (CGT) • Vaccines & Viral Vector Production • Protein Therapeutics Together, the two companies aim to establish a GMP-compliant QC automation system and enhance process reproducibility for commercial-scale bioproduction. |
| Previous post | KSBMB 2026 |
|---|---|
| Next post | Bio Asia-Taiwan 2026 |
